Eisai commences full-scale operation of new production site

Strengthening in-house domestic production system in China

09-Nov-2018 - Eisai Co., Ltd. announced that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly. Aiming to further expand its contribution to patients in China, Eisai ...

Swissmedic Approves Zonegran (zonisamide) Monotherapy Treatment for Epilepsy

15-Jul-2013 - Zonegran (zonisamide) has today been approved by Swissmedic for the monotherapy treatment of partial seizures (with or without secondary generalisation) in adults with newly diagnosed epilepsy. Monotherapy is when treatment is given with one single drug.Already a successful add-on therapy, ...

Eisai: Halaven Receives Approval in Japan for the Treatment of Inoperable and Recurrent Breast Cancer

26-Apr-2011 - Eisai Co., Ltd. announced that it has received approval to market its anticancer Halaven(R) Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer. Discovered and developed by Eisai, Halaven is now approved in each of the world's three largest ...

Eisai's Halaven Receives CHMP Positive Opinion for use in Metastatic Breast Cancer

CHMP Opinion Based on Positive EMBRACE Study Data

24-Jan-2011 - The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), gave a positive opinion for the use of Eisai Europe, Ltd.'s Halaven as a monotherapy indicated in the treatment of patients with locally advanced (LA) or metastatic ...

Eisai Announces Positive Phase III Trial Results for Perampanel in Partial Epilepsy

27-Aug-2010 - Eisai announced the results of a Phase III study for the investigational compound perampanel (E2007), a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered by Eisai and under development for adjunctive treatment of partial seizures in patients with ...

Eisai Opens Regional Office in Bahrain

19-Oct-2009 - Eisai Co., Ltd. announced the opening of a regional office in Bahrain. The new office has been established as a branch of its Asian headquarters Eisai Asia Regional Services Pte. Ltd. Eisai started doing business with the Middle East in the 1960’s. It has since focused on the sale of products ...

Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer’s Disease in Japan

24-Jul-2009 - Eisai Co., Ltd. announced that the Company had received approval for a new oral jelly formulation of Aricept® (donepezil hydrochloride) for the treatment of Alzheimer’s disease from the Japanese Ministry of Health, Labour and Welfare. The new oral jelly formulation is easier for patients with ...

SymBio Pharmaceuticals and Eisai Sign License Agreement for bendamustine hydrochloride (SyB L-0501)

19-Aug-2008 - SymBio Pharmaceuticals Limited. and Eisai Co., Ltd. announced that the companies have concluded the license agreement for the co-development and commercialization of bendamustine hydrochloride in Japan, with exclusive rights retained by SymBio. Based on this agreement, SymBio shall grant ...

Eisai invests in BioArctic's Alzheimer research

Japanese firm inputs world-leading know-how in next-generation treatment

07-Apr-2008 - Eisai Co. Ltd has signed an exclusive licence agreement with Uppsala-based biopharmaceutical company BioArctic Neuroscience for their monoclonal antibody BAN2401, developed as a next-generation treatment for Alzheimer's Disease. The amount invested in the joint R&D project has not been disclosed ...

M's Science and Eisai Sign Option Agreement for Sigma Agonist SA4503

14-Mar-2008 - M's Science Corporation and Eisai Co., Ltd. announced that the companies entered into an option agreement for SA4503, a novel sigma agonist which is being developed by M's Science in Europe for the treatment of depression and post-stroke therapy. Under the terms of the agreement, M's Science ...